Robert W. Baird Downgrades Cambrex (CBM) to Neutral

Robert W. Baird cut shares of Cambrex (NYSE:CBM) from an outperform rating to a neutral rating in a report issued on Friday morning, Benzinga reports. The firm currently has $44.00 price objective on the biotechnology company’s stock. The analysts noted that the move was a valuation call.

A number of other analysts have also recently weighed in on the company. Jefferies Financial Group cut Cambrex from a buy rating to a hold rating and set a $43.00 price target on the stock. in a research report on Friday, February 22nd. ValuEngine upgraded Cambrex from a strong sell rating to a sell rating in a research report on Friday, February 22nd. Craig Hallum dropped their price target on Cambrex from $71.00 to $45.00 and set a buy rating on the stock in a research report on Thursday, February 14th. Finally, Zacks Investment Research cut Cambrex from a buy rating to a hold rating in a research report on Tuesday, February 12th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $47.80.

Shares of Cambrex stock opened at $47.20 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.86 and a current ratio of 3.93. The company has a market cap of $1.55 billion, a PE ratio of 17.04, a P/E/G ratio of 4.05 and a beta of 2.41. Cambrex has a twelve month low of $33.80 and a twelve month high of $69.43.

Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The business had revenue of $159.46 million for the quarter, compared to analysts’ expectations of $159.71 million. Cambrex had a return on equity of 12.31% and a net margin of 14.35%. The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.72 EPS. As a group, research analysts expect that Cambrex will post 1.14 EPS for the current year.

In related news, COO Shawn Cavanagh sold 6,769 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $37.60, for a total value of $254,514.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Gregory Sargen sold 5,802 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $37.45, for a total value of $217,284.90. The disclosure for this sale can be found here. 1.41% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CBM. Mackenzie Financial Corp increased its position in Cambrex by 41.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,487,875 shares of the biotechnology company’s stock valued at $56,182,000 after acquiring an additional 434,406 shares during the period. Norges Bank acquired a new stake in Cambrex in the 4th quarter valued at approximately $12,632,000. Copper Rock Capital Partners LLC increased its position in Cambrex by 161.4% in the 4th quarter. Copper Rock Capital Partners LLC now owns 391,490 shares of the biotechnology company’s stock valued at $14,771,000 after acquiring an additional 241,749 shares during the period. Clearbridge Investments LLC increased its position in Cambrex by 13.7% in the 3rd quarter. Clearbridge Investments LLC now owns 1,315,434 shares of the biotechnology company’s stock valued at $89,976,000 after acquiring an additional 158,268 shares during the period. Finally, BlackRock Inc. increased its position in Cambrex by 3.2% in the 4th quarter. BlackRock Inc. now owns 4,885,273 shares of the biotechnology company’s stock valued at $184,469,000 after acquiring an additional 153,664 shares during the period.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

See Also: Percentage Decliners

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.